Previous 10 | Next 10 |
2023-12-12 07:30:06 ET DENVER, Colo., Dec 12, 2023 ( www.247marketnews.com )- IN8bio, Inc. IN8bio Inc (NASDAQ: INAB) reported, after yesterday’s market close, positive updated data from its Phase 1 investigator-sponsored trial of INB-100 in patients with hematologic malignancies,...
Durable complete remission (CR) achieved in 100% of treated patients, including high-risk and relapsed acute myeloid leukemia (AML) patients and those who had failed multiple prior lines of therapy, including CAR-T. All trial participants remain alive and relapse free as of last asses...
2023-12-11 11:59:33 ET More on IN8bio Seeking Alpha’s Quant Rating on IN8bio Historical earnings data for IN8bio Financial information for IN8bio For further details see: IN8bio prices its $46.9M in private placement
Initial closing of $14.4 million to support operational execution and extend cash runway into 2025 with potential for up to $32.5 million in additional capital at increasing valuations Proceeds to help accelerate advancement of the Company’s gamma-delta T cell therapies NEW...
2023-12-10 07:30:00 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . For further details see: Wall Street Breakfast: The Week Ahead
2023-12-08 15:00:12 ET More on the markets S&P 500: New All-Time Highs Before A Major Sell-Off S&P 500 Forecast 2024: Muddling Through Only Thing That Matters Is Price; Nasdaq Has Further To Go - Cestrian Capital Research Money market funds attract mo...
Internationally recognized immuno-oncology and cell therapy executive with 20 years of experience in innovative immunotherapies for solid and hematological cancers Board-Certified physician-scientist with deep experience at leading organizations such as Bristol Myers Squibb, Iovance B...
Event will follow the presentation of INB-100 data in patients with hematologic malignancies at the American Society of Hematology (ASH) 65 th Annual Meeting & Exposition on the evening of December 11, 2023 IN8bio’s management team will be joined by clinical thoug...
All patients treated with INB-200 who completed mandated doses to date have exceeded a progression-free survival (PFS) of seven months Most patients exceeded the expected median PFS based on age and tumor status; two patients from Cohort 2 remain alive beyond two years Additiona...
Company will present “late-breaker” poster detailing updated clinical data from Phase 1 trial of INB-200 Company-sponsored Phase 2 trial of INB-400 to be showcased in Trials-in-Progress (TIPs) poster NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INA...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will participate in a fireside chat during the H.C. Wainwrigh...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 1.8% to $131.88 on volume of 307,014,213 shares SRIVARU Holding Limited (SVMH) rose 49.2% to $0.2275 on volume of 274,465,266 shares Nauticus Robotics Inc. (KITT) rose 19.6% to $0.192 on volume of 161,46...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...